OIM
RGLS

Oracle Investment Management’s Regulus Therapeutics RGLS Stock Holding History

Oracle Investment Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-3,121
Closed -$2.45M – 24
2015
Q3 		$2.45M Sell
3,121
-3,061
-50% -$3.14M 0.5% 20
2015
Q2 		$8.13M Sell
6,182
-4,544
-42% -$7.33M 0.99% 21
2015
Q1 		$21.8M Buy
+10,726
New +$23.3M 2.77% 15

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Oracle Investment Management's RGLS Position: Q4 2015 in Review

Oracle Investment Management sold out of Regulus Therapeutics (RGLS) in Q4 2015, closing a stake of 3,121 shares — an estimated $2.45M sold.

Oracle Investment Management first reported a position in RGLS in Q1 2015 and held it in 3 quarters. The position peaked at $21.8M in Q1 2015. 103 funds tracked by Wall St. Rank hold RGLS as of Q4 2015.

  • Oracle Investment Management reported no remaining Regulus Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Oracle Investment Management sold 3,121 Regulus Therapeutics shares in Q4 2015, an estimated $2.45M.
  • Oracle Investment Management first reported a position in Regulus Therapeutics in Q1 2015 and held it in 3 quarters.
  • Oracle Investment Management's Regulus Therapeutics position peaked at $21.8M in Q1 2015.
  • 103 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2015.

Based on Oracle Investment Management's 13F filing for Q4 2015, filed 9 Feb 2016.